ONCAlert | Upfront Therapy for mRCC

Gynecologic Cancers VIEW MORE >>

Overall survival was not improved with secondary cytoreduction followed by chemotherapy compared with chemotherapy alone in the phase III GOG-0213 trial, which missed its primary endpoint.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.